In vitro fertilization and systemic lupus erythematosus or antiphospholipid syndrome: An update;Fécondation in vitro au cours du lupus érythémateux systémique ou du syndrome des antiphospholipides: Mise au point

Revue de Medecine Interne

Volumn 36, Issue 3, 2015, Pages 154-158

  Orquevaux, P ^a   Masseau, A ^b   Le Guern, V ^c   Gayet, V ^d   Vauthier, D ^d   Boutin, D ^e   Wechsler, B ^e   Morel, N ^c   Guettrot Imbert, G ^f   Pennaforte, J L ^a   Piette, J C ^e   Costedoat Chalumeau, N ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Antiphospholipid syndrome; Assisted reproductive technology; In vitro fertilization; Infertility; Systemic lupus erythematosus

Indexed keywords

ANTIPHOSPHOLIPID SYNDROME; DISEASE EXACERBATION; FERTILIZATION IN VITRO; HUMAN; LUPUS FLARE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATIENT COMPLIANCE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; ADVERSE EFFECTS; COMPLICATION; FEMALE; IN VITRO FERTILIZATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PROCEDURES;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; FERTILIZATION IN VITRO; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY;

EID: 84925247329     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2014.08.004     Document Type: Short Survey

References (53)

1. Costa M., Colia D. Treating infertility in autoimmune patients. Rheumatology 2008, 47:38-41.
2. Carré-Pigeon F., Schubert B. Demande de préservation de la fertilité chez la femme en cas de maladie auto-immune: possibilités et pratiques en France. Gynecol Obstet Fertil 2007, 35:853-860.
3. Lateef A., Petri M. Management of pregnancy in systemic lupus erythematosus. Nat Rev Rheumatol 2012, 8:710-718.
4. Guballa N., Sammaritano L., Schwartzman S., Buyon J., Lockshin M.D. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000, 43:550-556.
5. Huong D.L.T., Wechsler B., Piette J.-C., Arfi S., Gallinari C., Darbois Y., et al. Risks of ovulation-induction therapy in systemic lupus erythematosus. Rheumatology 1996, 35:1184-1186.
6. Ben-Chetrit A., Ben-Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis Rheum 1994, 37:1614-1617.
7. Benshushan A., Shushan A., Paltiel O., Mordel N., Laufer N. Ovulation induction with clomiphene citrate complicated by deep vein thrombosis. Eur J Obstet Gynecol Reprod Biol 1995, 62:261-262.
8. Casoli P., Tumiati B., La Sala G. Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 1997, 24:1639-1640.
9. Huong D.L.T., Wechsler B., Vauthier-Brouzes D., Duhaut P., Costedoat N., Lefebvre G., et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21cases and 114cycles. Semin Arthritis Rheum 2002, 32:174-188.
10. Orquevaux P., Masseau A., Le Guern V., Gayet V., Vauthier-Brouzes D., Boutin D., et al. In vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome: a serie of 82cycles. Arthritis Rheum 2013, 65:1090. [Abstract].
11. Bellver J., Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril 2009, 92:1803-1810.
12. Le Thi Huong D., Wechsler B., Piette J.C. Ovulation induction therapy and systemic lupus erythematosus. Ann Med Interne Paris 2003, 154:45-50.
13. Hickman R.A., Gordon C. Causes and management of infertility in systemic lupus erythematosus. Rheumatology 2011, 50:1551-1558.
14. Janssen N.M., Genta M.S. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000, 160:610.
15. Østensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8:209.
16. Boumpas D.T., Austin H.A., Vaughan E.M., Yarboro C.H., Klippel J.H., Balow J.E. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993, 119:366-369.
17. Blummenfeld Z., Shapiro D., Shteinberg M., Avivi I., Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000, 9:401-405.
18. Manger K., Wildt L., Kalden J.R., Manger B. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erytthematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 2005, 5:269-272.
19. Marder W., McCune W.J., Wang L., Wing J.J., Fisseha S., McConnell D.S., et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol 2012, 28:624-627.
20. Somers E.C., Marder W., Christman G.M., Ognenovski V., McCune W.J. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005, 52:2761-2767.
21. Carp H.J., Shoenfeld Y. Anti-phospholipid antibodies and infertility. Clin Rev Allergy Immunol 2007, 32:159-161.
22. Stern C., Chamley L., Hale L., Kloss M., Speirs A., Baker H.W. Antibodies to beta2glycoprotein I are associated with in vitro fertilization implantation failure as well as reccurent miscarriage: results of a prevalence study. Fertil Steril 1998, 70:938-944.
23. Cervera R., Balasch J. Bidirectional effects on autoimmunity and reproduction. Hum Reprod Update 2008, 14:359-366.
24. Balasch J., Creus M., Fabreques F., Reverter J.C., Carmona F., Tassies D., et al. Antiphospholipid antibodies and human reporductive failure. Hum Reprod Oxf Engl 1996, 11:2310-2315.
25. Hornstein M.D., Davis O.K., Massey J.B., Paulson R.J., Collins J.A. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000, 73:330-333.
26. Frydman R., Cornel C., de Ziegler D., Taieb J., Spitz I.M., Bouchard P. Prevention of premature luteinizing hormone and progesterone rise with a gonadotrophin-releasing hormone antagonist. Nal-Glu, in controlled ovarian hyperstimulation. Fertil Steril 1991, 56:923-927.
27. Gonen Y., Balakier H., Powell W., Casper R.F. Use of gonadotrophin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990, 71:918-922.
28. Humaidan P., Kol S., Papanikolaou E.G., Copenhagen GnRH Agonist Triggering Workshop Group GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Hum Reprod Update 2011, 17:510-524.
29. Chan W.S., Dixon M.E. The "ART" of thromboembolism: review of assisted reproductive technology and thromboembolic complications. Thromb Res 2008, 121:713-726.
30. Rova K., Passmark H., Lindgvist P.G. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk successful cycles. Fertil Steril 2011, 97:95-100.
31. Askanase A.D., Buyon J.P. Reproductive health in SLE. Best Pract Res Clin Rheumatol 2002, 16:265-280.
32. Le Thi Huong D., Wechsler B., Piette J.C. Induction d'ovulation, lupus et antiphospholipides. Rev Med Interne 2001, 22:111-117.
33. Stewart J.A., Hamilton P.J., Murdoch A.P. Thromboembolic disease associated with ovarian stimulation and assisted conception techniques. Hum Reprod 1997, 12:2167-2173.
34. Wechsler B., Le Thi Huong D., Vauthier-Brouzes D., Lefebvre G., Gompel A., Piette J.C. Can we advise ovulation induction in patients with SLE?. Scand J Rheumatol Suppl 1998, 107:53-59.
35. Delvigne A., Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002, 8:559-577.
36. Crochet J.R., Yeh J.S., Clowse M.E.B., Copland S.D. Late ovarian hyperstimulation syndrome after controlled ovarian stimulation in a woman with systemic lupus erythematosus and lupus nephritis. Fertil Steril 2011, 95:e13-e16.
37. Papanikolaou E.G., Pozzobon C., Kolibiananakis E.M., Camus M., Tournaye H., Fatemi H.M., et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotrophin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006, 85:112-120.
38. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2013, 18:630-634.
39. Aboulghar M. Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. Hum Reprod 2003, 18:1140-1141.
40. Aboulghar M. Agonist and antagonist coast. Fertil Steril 2012, 97:523-526.
41. Al-Inany H.G., Youssef M.A., Aboulghar M., Broekmans F., Sterrenburg M., Smit J., et al. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update 2011, 17:435.
42. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., Benadiva C. The use of gonadotrophin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2007, 89:84-91.
43. Griesinger G., Schultz L., Bauer T., Broessner A., Frambach T., Kisser S. Ovarian hyperstimulation syndrome prevention by gonadotrophin-releasing hormone agonist triggering of final oocyte maturation in a gonadotrophin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. Fertil Steril 2011, 95:2029-2033.
44. Cobo A., de los Santos M.J., Castello D., Gamiz P., Campos P., Remohi J. Outcomes of vitrified early cleavage-stage and blastocyt-stage embryos in a cryopreservation program: evaluation of 3,150warming cycles. Fertil Steril 2012, 98:1138-1146.
45. Manzanares M.A., Gomez-Palomares J.L., Ricciarelli E., Hernandez E.R. Triggering ovulation with gonadotrophin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril 2010, 93:215-219.
46. Giner V., Oltra M.R., Esteban M.J., Garcia-Fuster M.J., Salvador A., Nunez J., et al. Castastrophic antiphospholipid syndrome related to severe ovarian hyperstimulation. Clin Rheumatol 2007, 26:991-993.
47. Andrejevic S., Bonaci-Nikolic B., Bukilica M., Macut D., Miljic P., Pavlovic M., et al. Intracardiac thrombosis and fever possibly triggered by ovulation in a patient with antiphospholipid antibodies. Scand J Rheumatol 2002, 31:249-251.
48. Geva E., Lerner-Geva L., Burke M., Vardinon N., Lessing J.B., Amit A. Undiagnosed systemic lupus erythematosus in a cohort of infertile women. Am J Reprod Immunol 2004, 51:336-340.
49. Conard J., Horellou M.H., Samama M.M., American College of Chest Physicians (ACCP) Pregnancy and venous thromboembolism. North-American and European guidelines. J Mal Vasc 2009, 34:825-835.
50. Dargaud Y., Rugeri L., Vergnes M.C., Arnuti B., Miranda P., Negrier C., et al. A risk score for the managment of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study. Br J Haematol 2009, 145:825-835.
51. Costedoat-Chalumeau N., Guettrot-Imbert G., Leroux G., Leguern V., Le Thi Huong D., Weschler D., et al. Grossesse et syndrome des antiphospholipides. Rev Med Interne 2012, 33:209-216.
52. Costedoat-Chalumeau N., Le Guern V., Piette J.C. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013, 27:329-340.
53. Smyth A., Oliveira G.H.M., Lahr B.D., Bailey K.R., Norby S.M., Garovic V.D. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010, 5:2060-2068.